Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
|Videos|November 9, 2021
Sheryl Kingsberg, PhD, presents paper of the year at NAMS 2021
Author(s)Lindsey Carr, Editor
Past president Sheryl Kingsberg, PhD, discusses the paper she chose to present as paper of the year at NAMS 2021.
Advertisement
Advertisement
Related to this article
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Open-ended questions help ob-gyns untangle GSM and low desire and build adherence-focused treatment plans, according to Sheryl Kingsberg, PhD.
Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.
Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
2
FAQ: Who is a candidate for testosterone therapy in women?
3
FAQ: What does the evidence show about testosterone in women?
4
Q&A: Kanchi Chadha, MD, FACOG, MSCP, on FDA boxed warning removals
5